Severe gastrointestinal inflammation could occur in 2 percent to 3 percent of patients who receive Carvykti, the FDA has informed patients and doctors.

The drugmaker said it plans to submit a regulatory application for DB-OTO to the FDA later this year, pending discussions with the agency.

The firm continues to seek needed funds to launch a Phase I/II trial of ELP-02 for this extremely rare form of ...

The initiative comprises academic institutions, charities, and companies pursuing a broad range of novel diagnostic and ...

The company expects top-line results in 2026 from this group of the basket trial testing the drug plixorafenib as a ...

The trial will include up to 78 patients with KRAS G12D-mutant pancreatic, colorectal, and non-small cell lung cancer.

Some genetics experts felt the event raised awareness of the importance of testing, while others had mixed feelings amid ...

The study found that patients with luminal B subtype prostate cancer benefited from the addition of hormone therapy to ...

The deal will bolster BMS's cell therapy efforts by adding Orbital's lead program in autoimmune diseases and RNA platform to its portfolio.

NEW YORK – Kernal Biologics on Tuesday said the Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to $48 million to support development of its in vivo mRNA-encoded CAR ...

Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...

The drugmaker is transitioning to Trialbee's Honey platform to better screen patients, including for biomarker information, ...